Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations
Targeted protein degradation (TPD) is a promising strategy for drug development. In this proof-of-concept study, the authors use telaprevir, which binds hepatitis C virus (HCV) NS3/4A protease, to target the protease for protein degradation, and show inhibition of wildtype as well as drug resistant...
Guardado en:
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5d5842f94e6549918072db60b50a3ebb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:5d5842f94e6549918072db60b50a3ebb |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:5d5842f94e6549918072db60b50a3ebb2021-12-02T16:58:03ZSmall molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations10.1038/s41467-019-11429-w2041-1723https://doaj.org/article/5d5842f94e6549918072db60b50a3ebb2019-08-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-11429-whttps://doaj.org/toc/2041-1723Targeted protein degradation (TPD) is a promising strategy for drug development. In this proof-of-concept study, the authors use telaprevir, which binds hepatitis C virus (HCV) NS3/4A protease, to target the protease for protein degradation, and show inhibition of wildtype as well as drug resistant HCV.Mélissanne de WispelaereGuangyan DuKatherine A. DonovanTinghu ZhangNicholas A. EleuteriJingting C. YuanJoann KalabathulaRadosław P. NowakEric S. FischerNathanael S. GrayPriscilla L. YangNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-11 (2019) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Science Q |
spellingShingle |
Science Q Mélissanne de Wispelaere Guangyan Du Katherine A. Donovan Tinghu Zhang Nicholas A. Eleuteri Jingting C. Yuan Joann Kalabathula Radosław P. Nowak Eric S. Fischer Nathanael S. Gray Priscilla L. Yang Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations |
description |
Targeted protein degradation (TPD) is a promising strategy for drug development. In this proof-of-concept study, the authors use telaprevir, which binds hepatitis C virus (HCV) NS3/4A protease, to target the protease for protein degradation, and show inhibition of wildtype as well as drug resistant HCV. |
format |
article |
author |
Mélissanne de Wispelaere Guangyan Du Katherine A. Donovan Tinghu Zhang Nicholas A. Eleuteri Jingting C. Yuan Joann Kalabathula Radosław P. Nowak Eric S. Fischer Nathanael S. Gray Priscilla L. Yang |
author_facet |
Mélissanne de Wispelaere Guangyan Du Katherine A. Donovan Tinghu Zhang Nicholas A. Eleuteri Jingting C. Yuan Joann Kalabathula Radosław P. Nowak Eric S. Fischer Nathanael S. Gray Priscilla L. Yang |
author_sort |
Mélissanne de Wispelaere |
title |
Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations |
title_short |
Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations |
title_full |
Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations |
title_fullStr |
Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations |
title_full_unstemmed |
Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations |
title_sort |
small molecule degraders of the hepatitis c virus protease reduce susceptibility to resistance mutations |
publisher |
Nature Portfolio |
publishDate |
2019 |
url |
https://doaj.org/article/5d5842f94e6549918072db60b50a3ebb |
work_keys_str_mv |
AT melissannedewispelaere smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT guangyandu smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT katherineadonovan smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT tinghuzhang smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT nicholasaeleuteri smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT jingtingcyuan smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT joannkalabathula smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT radosławpnowak smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT ericsfischer smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT nathanaelsgray smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations AT priscillalyang smallmoleculedegradersofthehepatitiscvirusproteasereducesusceptibilitytoresistancemutations |
_version_ |
1718382387362004992 |